OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
Rhea-AI Summary
OSR Holdings (NASDAQ:OSRH) will present its VXM01 global licensing agreement at the Emerging Growth Conference on May 7, 2026. The virtual presentation is scheduled for 4:10 p.m. ET and will include an overview and a live Q&A.
Tim Smith, Head of Investor Relations, will discuss the recently executed licensing agreement and answer investor questions. Registration is required for live attendance; an archived webcast will be available on EmergingGrowth.com, the Emerging Growth YouTube channel, and the company's Events & Presentations page.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – OSRH
On the day this news was published, OSRH gained 52.80%, reflecting a significant positive market reaction. Argus tracked a peak move of +25.9% during that session. Argus tracked a trough of -13.0% from its starting point during tracking. Our momentum scanner triggered 59 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $27.85M at that time. Trading volume was exceptionally heavy at 166.9x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer action appears mixed: in the momentum set, PHGE is down ~4.68% while BCDA is up ~4.55%. With the scanner flagging the target direction as up but peers split, this points to stock-specific dynamics rather than a broad biotechnology move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Definitive license deal | Positive | -38.2% | Signed $815M VXM01 global license with BCM Europe and related share pledges. |
| Apr 09 | Capital structure move | Positive | +3.8% | Convertible note transaction to retire $2.02M in warrants and cut dilution risk. |
| Mar 30 | Investor conference update | Positive | +13.8% | Planned Emerging Growth Conference update on VXM01 and Woori IO platform. |
| Mar 27 | Equity research note | Positive | +5.6% | Flash report reaffirmed Buy-Emerging rating and $10.00 target with VXM01 focus. |
| Mar 23 | Deal structure update | Positive | +9.6% | Revised VXM01 deal to route up to $815M milestones directly to OSR Holdings. |
News around the VXM01 licensing structure and investor outreach has usually been followed by positive price reactions, while the definitive license execution drew a sharp negative move.
Over the last month, OSR Holdings has focused on the VXM01 oncology asset and capital structure. Updates on the VXM01 licensing deal and related economics on Mar 23 and the Emerging Growth conference plans on Mar 30 were followed by gains. A research flash report on Mar 27 and an April warrant-restructuring transaction also saw positive reactions. By contrast, the Apr 29 definitive VXM01 global license agreement with up to $815 million in milestones coincided with a -38.19% move, highlighting market sensitivity to deal terms.
Market Pulse Summary
The stock surged +52.8% in the session following this news. A strong positive reaction aligns with prior instances where conference participation and VXM01-related updates supported gains, such as late March events with moves up to 13.84% and 9.59%. However, the recent definitive VXM01 deal on Apr 29 coincided with a -38.19% move, underscoring that deal structure and valuation concerns have weighed heavily. If enthusiasm were to fade, prior volatility and financing needs could contribute to sharp reversals.
AI-generated analysis. Not financial advice.
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. The presentation will provide investors and analysts with an overview of the Company's landmark VXM01 global licensing agreement and its implications for OSRH shareholders.
Virtual Presentation Details
Date: May 7, 2026
Time: 4:10 p.m. ET
Format: VXM01 Licensing Overview and Q&A
Registration: https://goto.webcasts.com/starthere.jsp?ei=1755070&tp_key=280dc3ffe3&sti=oshr
Tim Smith, Head of Investor Relations, will give an in-depth view of the recently executed VXM01 global licensing agreement, followed by a Q&A session. Investors are encouraged to submit questions in advance to Questions@EmergingGrowth.com or during the live event and management will address as many questions as possible.
Attendees are encouraged to register in advance. For those unable to attend live, an archived webcast will be available at EmergingGrowth.com, the Emerging Growth YouTube Channel, and in the "Events & Presentations" section of the Company's website OSR-Holdings.com.
To view the Company's previous presentation, visit:
https://www.youtube.com/watch?v=n7CjcvlFVzw&t=377s
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About OSR Holdings
OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.
Investor Contact
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable U.S. securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.
SOURCE: OSR Holdings, Inc.
View the original press release on ACCESS Newswire